NexImmune, Inc.
NEXIDelisted Sep 6, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001538210
NexImmune, Inc. was delisted on Sep 6, 2024; its insiders filed their last Form 4 on Jun 13, 2024; 13 institutions reported holding it in 13F filings for Q2 2024, worth $408.6K in total; no superinvestor held it.
13F holders, Q1 2024
Institutional positions in NexImmune, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 12
- +1 vs. Q4 2023
- Shares held
- 153.0K
- +49.5K (+47.9%) vs. Q4 2023
- Total value
- $858.3K
- +$628.9K (+274.2%) vs. Q4 2023
- New holders
- 4
- 1 more added
- Sold out
- 3
- 2 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NEXI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 1 | $2.70K |
| Q2 2024 | 13 | $408.6K |
| Q1 2024 | 12 | $858.3K |
| Q4 2023 | 11 | $229.4K |
| Q3 2023 | 31 | $921.4K |
| Q2 2023 | 32 | $1.26M |
| Q1 2023 | 31 | $2.20M |
| Q4 2022 | 29 | $1.45M |
| Q3 2022 | 39 | $4.34M |
| Q2 2022 | 46 | $13.4M |
| Q1 2022 | 52 | $40.1M |
| Q4 2021 | 46 | $47.1M |
| Q3 2021 | 47 | $160.3M |
| Q2 2021 | 42 | $119.0M |
| Q1 2021 | 46 | $184.9M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding NexImmune, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sabby Management, LLC | 59,851 | $335.8K | 2.20% | +59,851 | New |
| Slate Path Capital LP | 36,999 | $207.6K | 0.00% | 00.0% | Unchanged |
| EPIQ Capital Group, LLC | 15,624 | $87.7K | 0.03% | 00.0% | Unchanged |
| The PNC Financial Services Group, Inc. | 12,640 | $70.9K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 12,010 | $67.4K | 0.00% | +12,010 | New |
| Raymond James & Associates | 10,804 | $60.6K | 0.00% | +10,804 | New |
| Comerica Bank | 3,256 | $18.3K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 1,580 | $8.86K | 0.00% | −221−12.3% | Reduced |
| Royal Bank of Canada | 173 | $1.00K | 0.00% | −874−83.5% | Reduced |
| BNP Paribas Arbitrage, SA | 41 | $230 | 0.00% | +41 | New |
| Wells Fargo & Company | 7 | $39 | 0.00% | +2+40.0% | Added |
| UBS Group AG | 1 | $6 | 0.00% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 0 | $0 | 0.00% | −32,054−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −17−100.0% | Sold out |
| BlackRock Inc. | 0 | $0 | 0.00% | −14−100.0% | Sold out |